Alpha-B-Crystallin Effect on Mature Amyloid Fibrils: Different Degradation Mechanisms and Changes in Cytotoxicity

Olga V Stepanenko1, M I Sulatsky2, E V Mikhailova1

  • 1Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology, Russian Academy of Sciences, 4 Tikhoretsky Ave., St. Petersburg 194064, Russian.

Insights

Heat shock protein alpha-B-crystallin can degrade mature amyloid fibrils through two mechanisms. This highlights the need to study chaperone effects on existing amyloid plaques, not just their formation, to ensure safe therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Protein Misfolding Diseases

Background:

  • Amyloidosis is characterized by pathological amyloid fibril accumulation.
  • Chaperone-based therapies aim to inhibit fibril formation.
  • Mature amyloid fibrils in patients are often overlooked in therapeutic strategies.

Purpose of the Study:

  • To investigate the effect of chaperone proteins on mature amyloid fibrils.
  • To understand the mechanisms by which alpha-B-crystallin interacts with and degrades existing amyloid structures.
  • To evaluate the implications of these interactions for chaperone-based amyloidosis therapy.

Main Methods:

  • In vitro studies using alpha-B-crystallin and pre-formed amyloid fibrils.
  • Analysis of amyloid fibril structural changes (ordering, fragmentation) under varying conditions.
  • Assessment of cytotoxicity and seeding potential of treated amyloid fibrils.

Main Results:

  • Alpha-B-crystallin induces "fluffing" and "unweaving" of mature amyloid fibrils under physiological conditions, potentially increasing cytotoxicity.
  • Fibril degradation rate correlates with cluster size, not amino acid sequence.
  • Under acidic conditions, alpha-B-crystallin fragments fibrils without altering secondary structure, which may accelerate amyloid accumulation and enhance toxicity.

Conclusions:

  • Chaperone effects on mature amyloid fibrils, including under stress, are critical for effective and safe amyloidosis therapy.
  • Current chaperone-based strategies may need re-evaluation to account for interactions with existing amyloid deposits.
  • Understanding chaperone-amyloid interactions is essential to prevent unintended acceleration of disease progression.